Reengineering Drug Discovery and Development

Drugmakers have employed new technologies to reduce the cost and time and it takes develop drugs and produce therapies that more precisely target the underlying biology driving diseases. Boston-based Berg Pharma is using artificial intelligence with a variety of other technologies to reengineer the discovery and development process. We spoke to Niven Narain, co-founder, president, and chief technology officer of Berg, about the problems with drug development today, what makes his company's approach unique, and what its pipeline can tell us about whether the approach is working.